Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There are currently two clinically and molecularly defined forms of myotonic dystrophy: (1) myotonic dystrophy type 1 (DM1), also known as 'Steinert's disease'; and (2) myotonic dystrophy type 2 (DM2), also known as proximal myotonic myopathy. DM1 and DM2 are progressive multisystem genetic disorders with several clinical and genetic features in common. DM1 is the most common form of adult onset muscular dystrophy whereas DM2 tends to have a milder phenotype with later onset of symptoms and is rarer than DM1. This review will focus on the clinical features, diagnosis and management of DM1 and DM2 and will briefly discuss the recent advances in the understanding of the molecular pathogenesis of these diseases with particular reference to new treatments using gene therapy.

Original publication

DOI

10.1136/jnnp.2008.158261

Type

Journal article

Journal

J Neurol Neurosurg Psychiatry

Publication Date

04/2010

Volume

81

Pages

358 - 367

Keywords

Blotting, Southern, Chromosomes, Human, Pair 19, Creatine, DNA Sequence, Unstable, Dehydroepiandrosterone, Diagnosis, Differential, Facial Expression, Female, Genetic Therapy, Humans, Insulin-Like Growth Factor Binding Protein 1, Muscle, Skeletal, Myotonic Dystrophy, Myotonin-Protein Kinase, Point Mutation, Pregnancy, Prenatal Diagnosis, Prognosis, Protein-Serine-Threonine Kinases, RNA Splicing, Trinucleotide Repeat Expansion